Tenofovir-related nephrotoxicity in HIV-infected patients.
about
In vitro cytotoxicity and mitochondrial toxicity of tenofovir alone and in combination with other antiretrovirals in human renal proximal tubule cellsTenofovir renal proximal tubular toxicity is regulated by OAT1 and MRP4 transportersSimian immunodeficiency virus-infected macaques treated with highly active antiretroviral therapy have reduced central nervous system viral replication and inflammation but persistence of viral DNAPrevalence and risk factors associated to chronic kidney disease in HIV-infected patients on HAART and undetectable viral load in BrazilRenal function in HIV-infected children and adolescents treated with tenofovir disoproxil fumarate and protease inhibitorsRenal events among women treated with tenofovir/emtricitabine in combination with either lopinavir/ritonavir or nevirapineAcyclic nucleoside phosphonates: a key class of antiviral drugs.Tenofovir disoproxil fumarate for the treatment of HIV infection.WHO antiretroviral therapy guidelines 2010 and impact of tenofovir on chronic kidney disease in Vietnamese HIV-infected patients.Tenofovir-associated renal dysfunction in clinical practice: An observational cohort from western IndiaCystatin C and creatinine in an HIV cohort: the nutrition for healthy living study.Urinary biomarkers of kidney diseases in HIV-infected children.Renal safety of tenofovir containing antiretroviral regimen in a Singapore cohort.Antiretroviral therapy and the kidney: balancing benefit and risk in patients with HIV infection.HIV-associated renal diseases and highly active antiretroviral therapy-induced nephropathy.Review of tenofovir-emtricitabine.Tenofovir use and urinary biomarkers among HIV-infected women in the Women's Interagency HIV Study (WIHS).A review of cardiovascular and renal function monitoring: a consideration of older adults with HIV.Tenofovir for the treatment of hepatitis B virus.Pharmacogenetics of tenofovir treatment.Long term adverse effects related to nucleoside reverse transcriptase inhibitors: clinical impact of mitochondrial toxicity.Renal toxicity associated with tenofovir use.Antiretroviral drug-related toxicities - clinical spectrum, prevention, and management.Emerging antiretroviral drugs.Prevalence of chronic renal failure stage 3 or more in HIV-infected patients in Antwerp: an observational study.Effects of Entecavir and Tenofovir on Renal Function in Patients with Hepatitis B Virus-Related Compensated and Decompensated Cirrhosis.Proximal tubular dysfunction associated with tenofovir in an HVC-HIV co-infected patient undergoing HVC therapy.Hepatic and renal safety profile of tenofovir in HIV-infected patients with hepatitis C, including patients on interferon plus ribavirin.Monitoring of Renal Function among HIV-Infected Patients Receiving Tenofovir in a Resource-Limited Setting.Renal toxicity of long-term therapy with tenofovir in HIV-infected patients.Discovery and Development of Tenofovir Disoproxil FumarateTenofovir-induced renal toxicity in 324 HIV-infected, antiretroviral-naïve patientsTenofovir-induced renal tubular dysfunction among human immunodeficiency virus patients on antiretroviral therapy in Nigeria: Prospects for early detection of presymptomatic nephrotoxicity
P2860
Q24674939-EDED2723-63B3-4169-B3A9-FEE2DA7E56B9Q33845879-6B9630F7-2B3D-4782-A5FA-8CDC67123DA4Q33893665-10E87CB7-D580-49D0-932B-3762DA09D965Q34055914-1F04186C-FA9D-4577-A43E-457EBD5D81EAQ34136166-25CE1210-98AD-4B16-ADB4-E4B818963543Q34250879-513AF77D-6377-4977-A112-A4364C484C6DQ34464655-FC385DCA-F8F2-4E05-9776-0CC110F530ACQ34569309-3D884E86-DFD0-4873-97B4-ED00F08E8949Q35040358-2E5C21E5-2579-468E-AE1A-9052A0D6B37DQ35117296-27E0DC04-B321-4C0C-B19A-BF275D829EC6Q35604023-D16E250D-70E7-4F03-B125-811CE80D7541Q35934081-2B2EBE48-6A69-439E-A51B-B5617D287933Q36237157-3BFF033F-82F7-48D7-A461-32227E89CF28Q36407276-96D366B5-C8E4-42CC-A9C1-9BB32C70582DQ36451062-85C2F5D1-E0AA-4881-8A0F-30C636DD5361Q36663686-18F6C227-D53E-4BBF-990B-41D72B2FE5F2Q36955003-725CA90C-2DAC-46D5-A528-C329DBF11EDEQ37196037-7DABBCCE-A414-4817-989F-2CDE5A0120EAQ37605886-32D29362-3A0B-4ACE-89B1-44FDE71306CFQ37618231-7820F154-085C-4FC7-AEAC-1A9D32882E16Q37634512-3236DE90-6079-48D2-ABC4-4CB7BDDC754BQ37729160-C74028E9-9B2C-4CD5-8BD5-01C3CD9C7CE0Q38111430-69FD881B-3D11-4D9D-A396-887F72183306Q38167382-E5B85022-DFAC-495E-827E-56A82D95BE19Q38951176-7A661B9D-663E-4244-AC14-E8674BB7DFC3Q40145207-FC4AD4B9-7261-4FB0-A47D-2B01212B988DQ40321183-067E3E6B-BB4B-458D-8CC7-A1F22C88C6C5Q42996802-3FBEDA88-986C-4C15-B2B1-AE1634036968Q44172482-3B5E28C0-469B-4DB4-9CF4-276B44C42A91Q47819929-F5AC712B-7394-49A1-8A80-D542444AFF1FQ56786248-9E947B01-7253-4563-B8A0-1A60CF90D07DQ56985092-FC7F728F-6020-45AC-96A6-894690FCF1C6Q58795390-DACA84E4-572C-4AF7-80C8-9BAA8DDF1A26
P2860
Tenofovir-related nephrotoxicity in HIV-infected patients.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh-hant
name
Tenofovir-related nephrotoxicity in HIV-infected patients.
@en
Tenofovir-related nephrotoxicity in HIV-infected patients.
@nl
type
label
Tenofovir-related nephrotoxicity in HIV-infected patients.
@en
Tenofovir-related nephrotoxicity in HIV-infected patients.
@nl
prefLabel
Tenofovir-related nephrotoxicity in HIV-infected patients.
@en
Tenofovir-related nephrotoxicity in HIV-infected patients.
@nl
P2093
P1433
P1476
Tenofovir-related nephrotoxicity in HIV-infected patients.
@en
P2093
Ana Barrios
Juan González-Lahoz
Teresa García-Benayas
P304
P356
10.1097/00002030-200404090-00019
P407
P577
2004-04-01T00:00:00Z